Skip to main content
Erschienen in:

01.04.2021 | Computed Tomography

Systemic mastocytosis revisited with an emphasis on skeletal manifestations

verfasst von: Antonio Leone, Marianna Criscuolo, Consolato Gullì, Antonella Petrosino, Nicola Carlo Bianco, Cesare Colosimo

Erschienen in: La radiologia medica | Ausgabe 4/2021

Einloggen, um Zugang zu erhalten

Abstract

Systemic mastocytosis (SM) is a rare form of mastocytosis that can affect various organ systems. Bone involvement is the most common and prominent imaging feature in patients with SM regardless of the subtype. Furthermore, bone involvement is a prognostic factor as it may entail an aggressive course of the disease. Diagnosis is established by bone marrow biopsy complemented by imaging modalities such as radiography, CT, and magnetic resonance (MR) imaging. The radiographic and CT appearances are that of sclerotic, lytic, or mixed patterns with focal or diffuse distribution, involving primarily the axial skeleton and the ends of the long bones. Bone marrow infiltration is best recognized on MR imaging. Osteoporosis is common in SM; thus, a bone mineral density measurement at lumbar spine and proximal femur by dual-energy X-ray absorptiometry should be obtained. Imaging plays a huge part in the diagnostic process; when skeletal imaging findings are carefully interpreted and correlated with clinical features, they can lead to the suspicion of SM. The primary aims of this review article were to focus on the role of imaging in detection and characterization of skeletal patterns of SM and to discuss relevant clinical features that could facilitate prompt and correct diagnosis.
Literatur
1.
Zurück zum Zitat Kirshenbaum AS, Kessler SW, Goff JP, Metcalfe DD (1991) Demonstration of the origin of humanmast cells from CD34 + bone marrow progenitor cells. J Immunol 146:1410–1415PubMed Kirshenbaum AS, Kessler SW, Goff JP, Metcalfe DD (1991) Demonstration of the origin of humanmast cells from CD34 + bone marrow progenitor cells. J Immunol 146:1410–1415PubMed
3.
Zurück zum Zitat da Silva EZ, Jamur MC, Oliver C (2014) Mast cell function: a new vision of an old cell. J Histochem Cytochem 62(10):698–738PubMed da Silva EZ, Jamur MC, Oliver C (2014) Mast cell function: a new vision of an old cell. J Histochem Cytochem 62(10):698–738PubMed
4.
Zurück zum Zitat Kirshenbaum AS, Goff JP, Semere T, Foster B, Scott LM, Metcalfe DD (1999) Demonstration that human mast cells arise from a progenitor cell population that is CD34( + ), c-kit (+), and expresses aminopeptidase N (CD13). Blood 94(7):2333–2342PubMed Kirshenbaum AS, Goff JP, Semere T, Foster B, Scott LM, Metcalfe DD (1999) Demonstration that human mast cells arise from a progenitor cell population that is CD34( + ), c-kit (+), and expresses aminopeptidase N (CD13). Blood 94(7):2333–2342PubMed
5.
Zurück zum Zitat Horny HP, Metcalfe DD, Akin C et al (2017) Mastocytosis. In: Swerdlow SH et al (eds) WHO classification of tumors of hematopoietic and lymphoid tissues. International Agency for Research and Cancer , Lyon Horny HP, Metcalfe DD, Akin C et al (2017) Mastocytosis. In: Swerdlow SH et al (eds) WHO classification of tumors of hematopoietic and lymphoid tissues. International Agency for Research and Cancer , Lyon
6.
Zurück zum Zitat Pardanani A (2019) Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management. Am J Hematol 94(3):363–377PubMed Pardanani A (2019) Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management. Am J Hematol 94(3):363–377PubMed
7.
Zurück zum Zitat Amagai Y, Tanaka A, Matsuda A, Jung K, Ohmori K, Matsuda H (2013) Stem cell factor contributes to tumorigenesis of mast cells via an autocrine/paracrine mechanism. J Leukoc Biol 93(2):245–250PubMed Amagai Y, Tanaka A, Matsuda A, Jung K, Ohmori K, Matsuda H (2013) Stem cell factor contributes to tumorigenesis of mast cells via an autocrine/paracrine mechanism. J Leukoc Biol 93(2):245–250PubMed
8.
Zurück zum Zitat Arber DA, Orazi A, Hasserjian R et al (2016) The 2016 revision to the world health organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391–2405PubMed Arber DA, Orazi A, Hasserjian R et al (2016) The 2016 revision to the world health organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391–2405PubMed
9.
Zurück zum Zitat Monnier J, Georgin-Lavialle S, Canioni D et al (2016) Mast cell sarcoma: new cases and literature review. Oncotarget 7(40):66299–66309PubMedPubMedCentral Monnier J, Georgin-Lavialle S, Canioni D et al (2016) Mast cell sarcoma: new cases and literature review. Oncotarget 7(40):66299–66309PubMedPubMedCentral
10.
Zurück zum Zitat Pardanani A, Akin C, Valent P (2006) Pathogenesis, clinical features, and treatment advances in mastocytosis. Best Pract Res Clin Haematol 19:595–615PubMed Pardanani A, Akin C, Valent P (2006) Pathogenesis, clinical features, and treatment advances in mastocytosis. Best Pract Res Clin Haematol 19:595–615PubMed
11.
Zurück zum Zitat Travis WD, Li CY, Bergstralh EJ, Yam LT, Swee RG (1988) Systemic mast cell disease. Analysis of 58 cases and literature review. Med (Baltim) 67:345–368 Travis WD, Li CY, Bergstralh EJ, Yam LT, Swee RG (1988) Systemic mast cell disease. Analysis of 58 cases and literature review. Med (Baltim) 67:345–368
12.
Zurück zum Zitat Akin C, Metcalfe DD (2004) Systemic mastocytosis. Annu Rev Med 55:419–432PubMed Akin C, Metcalfe DD (2004) Systemic mastocytosis. Annu Rev Med 55:419–432PubMed
13.
Zurück zum Zitat Riffel P, Schwaab J, Lutz C et al (2020) An increased bone mineral density is an adverse prognostic factor in patients with systemic mastocytosis. J Cancer Res Clin Oncol 146(4):945–951PubMedPubMedCentral Riffel P, Schwaab J, Lutz C et al (2020) An increased bone mineral density is an adverse prognostic factor in patients with systemic mastocytosis. J Cancer Res Clin Oncol 146(4):945–951PubMedPubMedCentral
14.
Zurück zum Zitat Barete S, Assous N, de Gennes C et al (2010) Systemic mastocytosis and bone involvement in a cohort of 75 patients. Ann Rheum Dis 69(10):1838–1841PubMed Barete S, Assous N, de Gennes C et al (2010) Systemic mastocytosis and bone involvement in a cohort of 75 patients. Ann Rheum Dis 69(10):1838–1841PubMed
15.
Zurück zum Zitat Johansson C, Roupe G, Lindstedt G, Mellström D (1996) Bone density, bone markers and bone radiological features in mastocytosis. Age Ageing 25(1):1–7PubMed Johansson C, Roupe G, Lindstedt G, Mellström D (1996) Bone density, bone markers and bone radiological features in mastocytosis. Age Ageing 25(1):1–7PubMed
17.
Zurück zum Zitat Chiappetta N, Gruber B (2006) The role of mast cells in osteoporosis. Semin Arthritis Rheum 36(1):32–36PubMed Chiappetta N, Gruber B (2006) The role of mast cells in osteoporosis. Semin Arthritis Rheum 36(1):32–36PubMed
18.
Zurück zum Zitat McKenna MJ (1994) Histomorphometric study of mast cells in normal bone, osteoporosis and mastocytosis using a new stain. Calcif Tissue Int 55(4):257–259PubMed McKenna MJ (1994) Histomorphometric study of mast cells in normal bone, osteoporosis and mastocytosis using a new stain. Calcif Tissue Int 55(4):257–259PubMed
19.
Zurück zum Zitat Irie A, Takami M, Kubo H, Sekino-Suzuki N, Kasahara K, Sanai Y (2007) Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity. Bone 41:165–174PubMed Irie A, Takami M, Kubo H, Sekino-Suzuki N, Kasahara K, Sanai Y (2007) Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity. Bone 41:165–174PubMed
20.
Zurück zum Zitat Theoharides TC, Boucher W, Spear K (2002) Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol 128(4):344–350PubMed Theoharides TC, Boucher W, Spear K (2002) Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol 128(4):344–350PubMed
21.
Zurück zum Zitat Kinjo M, Setoguchi S, Solomon DH (2008) Anti-histamine therapy and bone mineral density: analysis in a population-based U.S. sample. Am J Med 121(12):1085–1091PubMedPubMedCentral Kinjo M, Setoguchi S, Solomon DH (2008) Anti-histamine therapy and bone mineral density: analysis in a population-based U.S. sample. Am J Med 121(12):1085–1091PubMedPubMedCentral
22.
Zurück zum Zitat Orsolini G, Viapiana O, Rossini M, Bonifacio M, Zanotti R (2018) Bone disease in mastocytosis. Immunol Allergy Clin North Am 38(3):443–454PubMed Orsolini G, Viapiana O, Rossini M, Bonifacio M, Zanotti R (2018) Bone disease in mastocytosis. Immunol Allergy Clin North Am 38(3):443–454PubMed
24.
Zurück zum Zitat Biosse-Duplan M, Baroukh B, Dy M, de Vernejoul MC, Saffar JL (2009) Histamine promotes osteoclastogenesis through the differential expression of histamine receptors on osteoclasts and osteoblasts. Am J Pathol 174(4):1426–1434PubMedPubMedCentral Biosse-Duplan M, Baroukh B, Dy M, de Vernejoul MC, Saffar JL (2009) Histamine promotes osteoclastogenesis through the differential expression of histamine receptors on osteoclasts and osteoblasts. Am J Pathol 174(4):1426–1434PubMedPubMedCentral
25.
Zurück zum Zitat de Gennes C, Kuntz D, de Vernejoul MC (1992) Bone mastocytosis. A report of nine cases with a bone histomorphometric study. Clin Orthop Relat Res 279:281–291 de Gennes C, Kuntz D, de Vernejoul MC (1992) Bone mastocytosis. A report of nine cases with a bone histomorphometric study. Clin Orthop Relat Res 279:281–291
27.
Zurück zum Zitat Lim KH, Tefferi A, Lasho TL et al (2009) Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood 113(23):5727–5736PubMed Lim KH, Tefferi A, Lasho TL et al (2009) Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood 113(23):5727–5736PubMed
28.
Zurück zum Zitat Kurian CJ, Madhavan I, Krishnankutty PK, Andrews MA (2014) Compressive myelopathy caused by isolated epidural myeloid sarcoma with systemic mastocytosis. Rare presentation of a hematological malignancy. Neurosciences 19(3):238–239 (Riyadh)PubMed Kurian CJ, Madhavan I, Krishnankutty PK, Andrews MA (2014) Compressive myelopathy caused by isolated epidural myeloid sarcoma with systemic mastocytosis. Rare presentation of a hematological malignancy. Neurosciences 19(3):238–239 (Riyadh)PubMed
29.
Zurück zum Zitat Zafar A, Frygier A, Strickland S, Turney R, Spink G (2020) A rare case of spinal mastocytosis presenting as an extradural mass. World Neurosurg 133:17–20PubMed Zafar A, Frygier A, Strickland S, Turney R, Spink G (2020) A rare case of spinal mastocytosis presenting as an extradural mass. World Neurosurg 133:17–20PubMed
30.
Zurück zum Zitat Theoharides TC, Valent P, Akin C (2015) Mast cells, mastocytosis, and related disorders. N Engl J Med 373(19):1885–1886PubMed Theoharides TC, Valent P, Akin C (2015) Mast cells, mastocytosis, and related disorders. N Engl J Med 373(19):1885–1886PubMed
31.
Zurück zum Zitat Butterfield JH, Weiler CR (2013) Systemic mastocytosis in the elderly. Am J Hematol 88(5):406–408PubMed Butterfield JH, Weiler CR (2013) Systemic mastocytosis in the elderly. Am J Hematol 88(5):406–408PubMed
32.
Zurück zum Zitat Harzy T, El Hajjaji A (2007) Osseous mastocytosis of the knee. Clin Rheumatol 26(12):2171–2172PubMed Harzy T, El Hajjaji A (2007) Osseous mastocytosis of the knee. Clin Rheumatol 26(12):2171–2172PubMed
33.
Zurück zum Zitat Delsignore JL, Dvoretsky PM, Hicks DG, O’Keefe RJ, Rosier RN (1996) Mastocytosis presenting as a skeletal disorder. Iowa Orthop J 16:126–134PubMedPubMedCentral Delsignore JL, Dvoretsky PM, Hicks DG, O’Keefe RJ, Rosier RN (1996) Mastocytosis presenting as a skeletal disorder. Iowa Orthop J 16:126–134PubMedPubMedCentral
34.
Zurück zum Zitat Fritz J, Fishman EK, Carrino JA, Horger MS (2012) Advanced imaging of skeletal manifestations of systemic mastocytosis. Skeletal Radiol 41(8):887–897PubMed Fritz J, Fishman EK, Carrino JA, Horger MS (2012) Advanced imaging of skeletal manifestations of systemic mastocytosis. Skeletal Radiol 41(8):887–897PubMed
35.
Zurück zum Zitat Hwang S, Panicek DM (2007) Magnetic resonance imaging of bone marrow in oncology, part 2. Skeletal Radiol 36(11):1017–1027PubMed Hwang S, Panicek DM (2007) Magnetic resonance imaging of bone marrow in oncology, part 2. Skeletal Radiol 36(11):1017–1027PubMed
36.
Zurück zum Zitat Shah LM, Hanrahan CJ (2011) MRI of spinal bone marrow: part I, techniques and normal age-related appearances. AJR Am J Roentgenol 197(6):1298–1308PubMed Shah LM, Hanrahan CJ (2011) MRI of spinal bone marrow: part I, techniques and normal age-related appearances. AJR Am J Roentgenol 197(6):1298–1308PubMed
37.
Zurück zum Zitat Benli IT, Akalin S, Boysan E et al (1992) Epidemiological, clinical and radiological aspects of osteopoikilosis. J Bone Jt Surg Br 74:504–506 Benli IT, Akalin S, Boysan E et al (1992) Epidemiological, clinical and radiological aspects of osteopoikilosis. J Bone Jt Surg Br 74:504–506
38.
Zurück zum Zitat Vanhoenacker FM, De Beuckeleer LH, Van Hul W et al (2000) Sclerosing bone dysplasias: genetic and radioclinical features. Eur Radiol 10(9):1423–1433PubMed Vanhoenacker FM, De Beuckeleer LH, Van Hul W et al (2000) Sclerosing bone dysplasias: genetic and radioclinical features. Eur Radiol 10(9):1423–1433PubMed
39.
Zurück zum Zitat Ihde LL, Forrester DM, Gottsegen CJ et al (2011) Sclerosing bone dysplasias: review and differentiation from other causes of osteosclerosis. Radiographics 31(7):1865–1882PubMed Ihde LL, Forrester DM, Gottsegen CJ et al (2011) Sclerosing bone dysplasias: review and differentiation from other causes of osteosclerosis. Radiographics 31(7):1865–1882PubMed
40.
Zurück zum Zitat Kanis JA (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report WHO Study Group. Osteoporos Int 4(6):368–381PubMed Kanis JA (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report WHO Study Group. Osteoporos Int 4(6):368–381PubMed
41.
Zurück zum Zitat Degboé Y, Eischen M, Nigon D et al (2017) Prevalence and risk factors for fragility fracture in systemic mastocytosis. Bone 105:219–225PubMed Degboé Y, Eischen M, Nigon D et al (2017) Prevalence and risk factors for fragility fracture in systemic mastocytosis. Bone 105:219–225PubMed
42.
Zurück zum Zitat Rossini M, Zanotti R, Bonadonna P et al (2011) Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis. Bone 49(4):880–885PubMed Rossini M, Zanotti R, Bonadonna P et al (2011) Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis. Bone 49(4):880–885PubMed
43.
Zurück zum Zitat Genant HK, Wu CY, van Kuijk C, Nevitt MC (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8(9):1137–1148PubMed Genant HK, Wu CY, van Kuijk C, Nevitt MC (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8(9):1137–1148PubMed
44.
Zurück zum Zitat van der Veer E, van der Goot W, de Monchy JG, Kluin-Nelemans HC, van Doormaal JJ (2012) High prevalence of fractures and osteoporosis in patients with indolent systemic mastocytosis. Allergy 67(3):431–438PubMed van der Veer E, van der Goot W, de Monchy JG, Kluin-Nelemans HC, van Doormaal JJ (2012) High prevalence of fractures and osteoporosis in patients with indolent systemic mastocytosis. Allergy 67(3):431–438PubMed
45.
Zurück zum Zitat Frenzel L, Suarez F, Chandesris MO, Hermine O (2012) Ivory vertebra and systemic mastocytosis. Jt Bone Spine 79(3):319–321 Frenzel L, Suarez F, Chandesris MO, Hermine O (2012) Ivory vertebra and systemic mastocytosis. Jt Bone Spine 79(3):319–321
46.
Zurück zum Zitat Chehab M, Copelan A, Al-faham Z, Bahoura L, Wong CY (2015) Systemic mastocytosis: a rare cause of single vertebral body uptake on bone scan. J Radiol Case Rep 9(2):31–41PubMedPubMedCentral Chehab M, Copelan A, Al-faham Z, Bahoura L, Wong CY (2015) Systemic mastocytosis: a rare cause of single vertebral body uptake on bone scan. J Radiol Case Rep 9(2):31–41PubMedPubMedCentral
47.
Zurück zum Zitat Graves L 3rd, Stechschulte DJ, Morris DC, Lukert BP (1990) Inhibition of mediator release in systemic mastocytosis is associated with reversal of bone changes. J Bone Miner Res 5(11):1113–1119PubMed Graves L 3rd, Stechschulte DJ, Morris DC, Lukert BP (1990) Inhibition of mediator release in systemic mastocytosis is associated with reversal of bone changes. J Bone Miner Res 5(11):1113–1119PubMed
48.
Zurück zum Zitat Chen CC, Andrich MP, Mican JM, Metcalfe DD (1994) A retrospective analysis of bone scan abnormalities in mastocytosis: correlation with disease category and prognosis. J Nucl Med 35(9):1471–1475PubMed Chen CC, Andrich MP, Mican JM, Metcalfe DD (1994) A retrospective analysis of bone scan abnormalities in mastocytosis: correlation with disease category and prognosis. J Nucl Med 35(9):1471–1475PubMed
49.
Zurück zum Zitat Avila NA, Ling A, Metcalfe DD, Worobec AS (1998) Mastocytosis: magnetic resonance imaging patterns of marrow disease. Skeletal Radiol 27(3):119–126PubMed Avila NA, Ling A, Metcalfe DD, Worobec AS (1998) Mastocytosis: magnetic resonance imaging patterns of marrow disease. Skeletal Radiol 27(3):119–126PubMed
50.
Zurück zum Zitat Barer M, Peterson LF, Dahlin DC, Winkelmann RK, Stewart JR (1968) Mastocytosis with osseous lesions resembling metastatic malignant lesions in bone. J Bone Jt Surg Am 50(1):142–152 Barer M, Peterson LF, Dahlin DC, Winkelmann RK, Stewart JR (1968) Mastocytosis with osseous lesions resembling metastatic malignant lesions in bone. J Bone Jt Surg Am 50(1):142–152
51.
Zurück zum Zitat Guglielmi G, Muscarella S, Bazzocchi A (2011) Integrated imaging approach to osteoporosis: state-of-the-art review and update. Radiographics 31(5):1343–1364PubMed Guglielmi G, Muscarella S, Bazzocchi A (2011) Integrated imaging approach to osteoporosis: state-of-the-art review and update. Radiographics 31(5):1343–1364PubMed
52.
Zurück zum Zitat Kropil P, Fenk R, Fritz LB et al (2008) Comparison of whole-body 64-slice multidetector computed tomography and conventional radiography in staging of multiple myeloma. Eur Radiol 18:51–58PubMed Kropil P, Fenk R, Fritz LB et al (2008) Comparison of whole-body 64-slice multidetector computed tomography and conventional radiography in staging of multiple myeloma. Eur Radiol 18:51–58PubMed
53.
Zurück zum Zitat Meyer HJ, Pönisch W, Monecke A, Gundermann P, Surov A (2020) Can diagnostic low-dose whole-body CT reflect bone marrow findings in systemic mastocytosis? Anticancer Res 40(2):1015–1022PubMed Meyer HJ, Pönisch W, Monecke A, Gundermann P, Surov A (2020) Can diagnostic low-dose whole-body CT reflect bone marrow findings in systemic mastocytosis? Anticancer Res 40(2):1015–1022PubMed
54.
Zurück zum Zitat Haney K, Russell W, Raila FA, Brower AC, Harrison RB (1996) MRI characteristics of systemic mastocytosis of the lumbosacral spine. Skeletal Radiol 25:171–173PubMed Haney K, Russell W, Raila FA, Brower AC, Harrison RB (1996) MRI characteristics of systemic mastocytosis of the lumbosacral spine. Skeletal Radiol 25:171–173PubMed
55.
Zurück zum Zitat Roca M, Mota J, Giraldo P, García Erce JA (1999) Systemic mastocytosis: MRI of bone marrow involvement. Eur Radiol 9(6):1094–1097PubMed Roca M, Mota J, Giraldo P, García Erce JA (1999) Systemic mastocytosis: MRI of bone marrow involvement. Eur Radiol 9(6):1094–1097PubMed
56.
Zurück zum Zitat Swartz PG, Roberts CC (2009) Radiological reasoning: bone marrow changes on MRI. AJR Am J Roentgenol 193(3 Suppl):S1-4PubMed Swartz PG, Roberts CC (2009) Radiological reasoning: bone marrow changes on MRI. AJR Am J Roentgenol 193(3 Suppl):S1-4PubMed
57.
Zurück zum Zitat Daldrup-Link HE, Henning T, Link TM (2007) MR imaging of therapy-induced changes of bone marrow. Eur Radiol 17(3):743–761PubMed Daldrup-Link HE, Henning T, Link TM (2007) MR imaging of therapy-induced changes of bone marrow. Eur Radiol 17(3):743–761PubMed
58.
Zurück zum Zitat Dreizin D, Ahlawat S, Del Grande F, Fayad LM (2014) Gradient-echo in-phase and opposed-phase chemical shift imaging: role in evaluating bone marrow. Clin Radiol 69:648–657PubMed Dreizin D, Ahlawat S, Del Grande F, Fayad LM (2014) Gradient-echo in-phase and opposed-phase chemical shift imaging: role in evaluating bone marrow. Clin Radiol 69:648–657PubMed
59.
Zurück zum Zitat Del Grande F, Farahani SJ, Carrino JA, Chhabra A (2014) Bone marrow lesions: a systematic diagnostic approach. Indian J Radiol Imaging 24(3):279–287PubMedPubMedCentral Del Grande F, Farahani SJ, Carrino JA, Chhabra A (2014) Bone marrow lesions: a systematic diagnostic approach. Indian J Radiol Imaging 24(3):279–287PubMedPubMedCentral
60.
Zurück zum Zitat Wasser K, Moehler T, Nosas-Garcia S et al (2005) Correlation of MRI and histopathology of bone marrow in patients with multiple myeloma. Rofo 177:1116–1122PubMed Wasser K, Moehler T, Nosas-Garcia S et al (2005) Correlation of MRI and histopathology of bone marrow in patients with multiple myeloma. Rofo 177:1116–1122PubMed
61.
Zurück zum Zitat Vande Berg BC, Lecouvet FE, Galant C, Simoni P, Malghem J (2009) Normal variants of the bone marrow at MR imaging of the spine. Semin Musculoskelet Radiol 13:87–96PubMed Vande Berg BC, Lecouvet FE, Galant C, Simoni P, Malghem J (2009) Normal variants of the bone marrow at MR imaging of the spine. Semin Musculoskelet Radiol 13:87–96PubMed
62.
Zurück zum Zitat Baur A, Stäbler A, Bartl R, Lamerz R, Scheidler J, Reiser M (1997) MRI gadolinium enhancement of bone marrow: age-related changes in normals and in diffuse neoplastic infiltration. Skelet Radiol 26(7):414–418 Baur A, Stäbler A, Bartl R, Lamerz R, Scheidler J, Reiser M (1997) MRI gadolinium enhancement of bone marrow: age-related changes in normals and in diffuse neoplastic infiltration. Skelet Radiol 26(7):414–418
63.
Zurück zum Zitat Morone M, Bali MA, Tunariu N et al (2017) Whole-body MRI: current applications in oncology. AJR Am J Roentgenol 209(6):W336–W349PubMed Morone M, Bali MA, Tunariu N et al (2017) Whole-body MRI: current applications in oncology. AJR Am J Roentgenol 209(6):W336–W349PubMed
64.
Zurück zum Zitat Lecouvet FE (2016) Whole-body MR Imaging: musculoskeletal applications. Radiology 279(2):345–365PubMed Lecouvet FE (2016) Whole-body MR Imaging: musculoskeletal applications. Radiology 279(2):345–365PubMed
65.
Zurück zum Zitat Riffel P, Jawhar M, Gawlik K et al (2019) Magnetic resonance imaging reveals distinct bone marrow patterns in indolent and advanced systemic mastocytosis. Ann Hematol 98(12):2693–2701PubMed Riffel P, Jawhar M, Gawlik K et al (2019) Magnetic resonance imaging reveals distinct bone marrow patterns in indolent and advanced systemic mastocytosis. Ann Hematol 98(12):2693–2701PubMed
66.
Zurück zum Zitat Padhani AR, Koh DM, Collins DJ (2011) Whole-body diffusion-weighted MR imaging in cancer: current status and research directions. Radiology 261(3):700–718PubMed Padhani AR, Koh DM, Collins DJ (2011) Whole-body diffusion-weighted MR imaging in cancer: current status and research directions. Radiology 261(3):700–718PubMed
67.
Zurück zum Zitat Arrington ER, Eisenberg B, Hartshorne MF, Vela S, Dorin RI (1989) Nuclear medicine imaging of systemic mastocytosis. J Nucl Med 30(12):2046–2048PubMed Arrington ER, Eisenberg B, Hartshorne MF, Vela S, Dorin RI (1989) Nuclear medicine imaging of systemic mastocytosis. J Nucl Med 30(12):2046–2048PubMed
68.
Zurück zum Zitat Zettinig G, Becherer A, Szabo M et al (2002) FDG positron emission tomography in patients with systemic mastocytosis. AJR Am J Roentgenol 179(5):1235–1237PubMed Zettinig G, Becherer A, Szabo M et al (2002) FDG positron emission tomography in patients with systemic mastocytosis. AJR Am J Roentgenol 179(5):1235–1237PubMed
69.
Zurück zum Zitat Djelbani-Ahmed S, Chandesris MO, Mekinian A et al (2015) FDG-PET/CT findings in systemic mastocytosis: a French multicentre study. Eur J Nucl Med Mol Imaging 42(13):2013–2020PubMed Djelbani-Ahmed S, Chandesris MO, Mekinian A et al (2015) FDG-PET/CT findings in systemic mastocytosis: a French multicentre study. Eur J Nucl Med Mol Imaging 42(13):2013–2020PubMed
70.
Zurück zum Zitat Rossignol J, Polivka L, Maouche-Chrétien L, et al (2019) Recent advances in the understanding and therapeutic management of mastocytosis. F1000Res 22;8:F1000 Faculty Rev-1961 Rossignol J, Polivka L, Maouche-Chrétien L, et al (2019) Recent advances in the understanding and therapeutic management of mastocytosis. F1000Res 22;8:F1000 Faculty Rev-1961
Metadaten
Titel
Systemic mastocytosis revisited with an emphasis on skeletal manifestations
verfasst von
Antonio Leone
Marianna Criscuolo
Consolato Gullì
Antonella Petrosino
Nicola Carlo Bianco
Cesare Colosimo
Publikationsdatum
01.04.2021
Verlag
Springer Milan
Erschienen in
La radiologia medica / Ausgabe 4/2021
Print ISSN: 0033-8362
Elektronische ISSN: 1826-6983
DOI
https://doi.org/10.1007/s11547-020-01306-8

Neu im Fachgebiet Radiologie

Ringen um den richtigen Umgang mit Zufallsbefunden

Wenn 2026 in Deutschland das Lungenkrebsscreening mittels Low-Dose-Computertomografie (LDCT) eingeführt wird, wird es auch viele Zufallsbefunde ans Licht bringen. Das birgt Chancen und Risiken.

Bald 5% der Krebserkrankungen durch CT verursacht

Die jährlich rund 93 Millionen CTs in den USA könnten künftig zu über 100.000 zusätzlichen Krebserkrankungen führen, geht aus einer Modellrechnung hervor. Damit würde eine von 20 Krebserkrankungen auf die ionisierende Strahlung bei CT-Untersuchungen zurückgehen.

Röntgen-Thorax oder LDCT fürs Lungenscreening nach HNSCC?

Personen, die an einem Plattenepithelkarzinom im Kopf-Hals-Bereich erkrankt sind, haben ein erhöhtes Risiko für Metastasen oder zweite Primärmalignome der Lunge. Eine Studie hat untersucht, wie die radiologische Überwachung aussehen sollte.

Statine: Was der G-BA-Beschluss für Praxen bedeutet

Nach dem G-BA-Beschluss zur erweiterten Verordnungsfähigkeit von Lipidsenkern rechnet die DEGAM mit 200 bis 300 neuen Dauerpatienten pro Praxis. Im Interview erläutert Präsidiumsmitglied Erika Baum, wie Hausärztinnen und Hausärzte am besten vorgehen.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.